Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...

Developing in vivo CAR T-cell therapies requires reliable approaches for transient, controlled CAR expression and targeted mRNA delivery to immune cells. This webinar will examine the transformative ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Researchers at the University of British Columbia developed a reliable method to produce helper T cells from stem cells by ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its FDA-approved therapy.

Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

However, hydrogen hasn’t yet caught on as a large-scale solution largely due to funding, even though even the US Department ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first ...